Recently, the Lingang Laboratory scientific research task project titled “Construction of Innovative ‘One Drug, Two Targets’ muRNA Nucleic Acid Drugs and Preclinical Research Targeting Dyslipidemia” was officially approved. This project is led by Professor Tang Xinjing’s team from Peking University, with Sirnaomics participating in the joint application.

Project Focus and Technology

This project addresses the major clinical demand for treating dyslipidemia. It focuses on key targets including:

● PCSK9
● ANGPTL3
● DGAT2

By leveraging Sirnaomics’ proprietary muRNA™ dual-target RNAi technology platform and the GalAhead™ liver-targeting delivery system, the project explores an innovative therapeutic path: using a single molecule to synergistically silence two targets. The goal is to develop nucleic acid drug candidates that are more efficient, long-lasting, precise, and possess greater potential for clinical translation.

Overcoming Limitations in Lipid-Lowering Therapy

Dyslipidemia—specifically elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG)—is a critical risk factor for atherosclerotic cardiovascular disease. While current lipid-lowering treatments have made significant strides, single-target therapies still face limitations when dealing with complex pathological mechanisms and high residual risks.

This newly approved project will conduct systematic research centered on the “one drug, two targets” strategy to:

● Further validate the innovative value of multi-target synergistic intervention in metabolic disease treatment.
● Establish a solid foundation for subsequent clinical translation.

Strategic Impact and Future Outlook

Sirnaomics has a long-standing commitment to nucleic acid drug R&D, having established mature technical systems in dual-target RNAi design, liver-targeting delivery, and preclinical efficacy and safety evaluation. The approval of this project signifies another step forward for the company in the innovative R&D of multi-target nucleic acid drugs. It also highlights the vital role of industry-academia-research synergy in driving original innovation and accelerating the transformation of scientific achievements.

Looking ahead, Sirnaomics will continue to collaborate with Peking University and other partners to steadily advance the project. The company strives to achieve representative breakthroughs in innovative nucleic acid drug R&D and metabolic disease treatment, ultimately providing patients with more valuable therapeutic options.

About Sirnaomics

Sirnaomics Ltd.(HK: 2257), known as Asia's "First RNAi Therapeutics Stock," is a clinical-stage global biopharmaceutical company specializing in RNA interference technology. Utilizing its dual core technology platforms and diverse pipeline, the company is at the forefront of developing RNAi therapies to drive industry growth.

Sirnaomics has two proprietary delivery platforms:

1. Polypeptide Nanoparticle (PNP) Platform: An extrahepatic delivery platform enabling precise targeting of tissues such as skin, adipose tissue, and muscle.
2. GalAhead™ Delivery Platform: A liver-targeted delivery system with clear IP and long-acting administration capabilities.

The company is also an industry leader with its innovative linker-free, dual-target RNAi technology. Sirnaomics' robust pipeline addresses oncology, local fat reduction, medical aesthetics, and cardiovascular diseases, with multiple products in clinical trials. Beyond its internal development, Sirnaomics embraces an open-collaboration strategy, integrating its technology platforms to support the broader industry and benefit patients worldwide.